Last week, Gilead failed in Phase 3 clinical trial for NASH drug. Today, Intercept has become the first player in the NASH area to complete a pivotal Phase 3 study in patients with liver fibrosis.
anonymous
Thread
clinical trials
drug
europe
fda
gilead
gilead sciences
intercept pharmaceuticals
liver fibrosis
nash
viking therapeutics
Ok, let's talk about salaries and bonuses across EU & Asia...
What is average salaries and bonuses in EU countries (including Russia and CIS) & Asia, and will they be payed this year?
So while all the bashing goes on and on about True Health why is no one talking about Boston actively engaging MSO schemes ie Kickbacks to physicians and waiving all copay and deductibles for OON claims? Business is being lost to these vultures for fraud and abuse practices yet crickets on the...
anonymous
Thread
bob gorman
dirk bontridder
eurofins
europe
jon hart
matt "in charge' urbanek
pat noland